Although histone modifying enzymes can be difficult to analyze by traditional methods, label-free RapidFire technology is well suited to this novel and emerging class of targets.
Assays for methylases, acetylases, phosphorylases and other modifying enzymes involved in histone and chromatin modulation are developed and optimized by BIOCIUS scientists for primary and secondary screens.
Screening Epigenetic Targets?
BIOCIUS RapidFire will help you get faster answers.
Our novel high-throughput screening platform accelerates the analysis of epigenetic targets, enabling our in-house scientists to deliver you more data, faster.
BIOCIUS scientists have successfully screened protein deacetylases (SIRT1, HDACs) and protein methylayses (LSD1). Let us help your HTS lab teams get the answers you need with our contract services.
Download our latest scientific poster:
"High Throughput Mass Spec Analysis of Histone 3 Demethylation"
Epigenetic Targets in Drug Discovery
Histone modifying enzymes are attractive therapeutic targets these days. The challenges that researchers have faced (up until now, anyway) include lengthy analysis times, unreliable results, and lack of sensitivity of traditional screening methods.
NOW: High-Throughput, Label-Free Screening of Epigenetic Targets
You get a fast, reproducible, set of data using BIOCIUS epigenetic contract research services. Our RapidFire mass spec platform has the ability to investigate reactions that are not practical using HPLC, fluorescence, or luminescence screening methodologies. RapidFire technology avoids some confounding effects such as auto-fluorescence. It can handle both 96 and 384 well formats.
In-house, PhD Level Research Scientists
BIOCIUS scientists have taken numerous targets from assay development through lead discovery and have screened tens of millions of test compounds from chemical libraries for clients in the pharmaceutical and biotechnology industries. Working with us you'll get the benefits of expert analysis, responsive customer support and fast data turnaround.
BIOCIUS. Faster Answers.
RapidFire® technology is described in patent numbers 6,932,939, 6,812,030 7,100,460, 7,588,725,